查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1606413

子宫内膜癌市场，按癌症类型、治疗类型、诊断方法、国家和地区 - 2024-2032 年行业分析、市场规模、市场份额和预测

Endometrial Cancer Market, By Type of Cancer, By Type of Therapy, By Diagnosis Method, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 303 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告要点

2023年子宫内膜癌市场规模为263.9453亿美元，2024年至2032年复合年增长率为5.80%。

子宫内膜癌市场-市场动态

子宫内膜癌盛行率的增加预计将推动市场扩张。

随着子宫内膜癌病例数量的增加，对高效率诊断工具和服务的需求不断增加。这包括使用超音波和 MRI 等成像技术以及活检程序。提高意识和筛检实践可以促进早期诊断，这对于提高治疗效果至关重要。根据世界癌症研究基金会国际报告，2022 年报告了 420,368 例子宫内膜癌新病例。然而，获得医疗服务的机会有限可能会阻碍市场成长。

子宫内膜癌市场 - 主要见解

根据我们的研究分析师分享的分析，预计全球市场在预测期内（2024-2032）每年将以 5.80% 左右的复合年增长率成长

根据癌症类型细分，预计子宫内膜癌将在 2023 年呈现最大市场份额

根据治疗类型细分，化疗是 2023 年的主导类型

根据诊断方法细分，活检是2023年的主导类型

按地区划分，北美是 2023 年的主要收入来源

子宫内膜癌市场-細項分析：

全球子宫内膜癌市场根据癌症类型、治疗类型、诊断方法和地区进行细分。

根据癌症类型，市场分为两类：子宫内膜癌、子宫肉瘤和其他。子宫内膜癌在市场上占据主导地位。子宫内膜癌是一种起源于子宫内膜（子宫内膜）的癌症。它占子宫癌的大部分，通常在停经后妇女中被诊断出来。

根据治疗类型，市场分为三个部分：免疫疗法、放射疗法、化疗和其他。化疗领域在市场上占据主导地位。它被广泛认为是晚期、復发性或侵袭性子宫内膜癌的主要治疗选择之一。

根据诊断方法，市场分为四大类：切片检查、骨盆超音波、子宫腔镜检查、CT 扫描等。活检在市场上占据主导地位。活检在子宫内膜癌的早期检测和诊断中的重要性至关重要，因为它们直接影响治疗选择以及对诊断工具和方法的需求。

子宫内膜癌市场 - 地理洞察

北美领先市场，主要归功于诊断方法的进步。该地区的特点是拥有强大的医疗保健系统，包括众多成熟的癌症治疗中心和专业设施，全部配备了尖端的诊断技术。该基础设施促进了癌症护理的整体方法，包括诊断和治疗。每年，约有 40 万名患者在 NCI 指定癌症中心被诊断出罹患癌症。由于意识的提高和筛检计划的实施，欧洲成为市场成长的第二大地区。随着各个地区的意识、诊断能力和治疗替代方案的不断增强，全球市场预计将进一步成长。

子宫内膜癌市场-竞争格局：

在诊断、治疗方式和致力于提高患者治疗效果的新兴技术创新的推动下，子宫内膜癌市场呈现高度竞争。许多公司正在争夺活检仪器、化疗药物、标靶治疗和免疫治疗等领域的市场份额。人们正在对研发进行大量投资，以创造新的治疗方案，包括免疫疗法、标靶疗法和联合疗法。液体活检和基因检测等进步因其在早期检测和个人化治疗策略方面的潜力而日益得到认可。能够有效通过监管审批流程的公司将能够获得竞争优势，特别是在免疫疗法等快速发展的领域。

最新进展：

2024 年 2 月 5 日，诺华宣布已达成协议，针对 MorphoSys AG 发起自愿公开收购竞标。

最近一项创新抗体药物的试验，直接对癌细胞进行强效化疗，目前正在针对晚期或復发性子宫内膜癌的患者进行 III 期研究。

目录

第一章：子宫内膜癌市场概述

  • 研究范围
  • 市场预估年份

第 2 章：执行摘要

  • 市场片段
    • 以癌症类型分類的子宫内膜癌市场片段
    • 依治疗类型分類的子宫内膜癌市场片段
    • 以诊断方法分類的子宫内膜癌市场片段
    • 按国家/地区分類的子宫内膜癌市场片段
    • 按地区分類的子宫内膜癌市场片段
  • 竞争洞察

第 3 章：子宫内膜癌主要市场趋势

  • 子宫内膜癌市场驱动因素
    • 市场驱动因素的影响分析
  • 子宫内膜癌市场限制
    • 市场限制影响分析
  • 子宫内膜癌市场机会
  • 子宫内膜癌市场未来趋势

第 4 章：子宫内膜癌产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第 5 章：子宫内膜癌市场：COVID-19 影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后影响分析
    • 表现最佳的市场区隔
    • 边际增长部分
    • 最鬆散的部分
    • 边际损失部分

第 6 章：子宫内膜癌市场模式

  • 2023 年子宫内膜癌市占分析
  • 按主要製造商分類的故障数据
    • 既定玩家分析
    • 新兴玩家分析

第 7 章：子宫内膜癌市场 - 依癌症类型

  • 概述
    • 按癌症类型分類的细分市场份额分析
    • 子宫内膜癌
    • 子宫肉瘤
    • 其他的

第 8 章：子宫内膜癌市场 - 依治疗类型

  • 概述
    • 按治疗类型分類的细分市场份额分析
    • 免疫治疗
    • 放射治疗
    • 化疗
    • 其他的

第 9 章：子宫内膜癌市场 - 依诊断方法

  • 概述
    • 依诊断方法进行细分市场份额分析
    • 活检
    • 骨盆腔超音波检查
    • 子宫腔镜检查
    • CT扫描
    • 其他的

第 10 章：子宫内膜癌市场 - 依地理位置

  • 介绍
    • 按地理位置分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美子宫内膜癌主要製造商
    • 北美市场规模和预测（按国家）
    • 北美市场规模和预测（按癌症类型）
    • 北美市场规模和预测（按治疗类型）
    • 北美市场规模和预测（按诊断方法）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲子宫内膜癌主要製造商
    • 欧洲市场规模和预测（按国家）
    • 欧洲市场规模和预测（按癌症类型）
    • 欧洲市场规模和预测（按治疗类型）
    • 欧洲市场规模和预测（按诊断方法）
    • 德国
    • 义大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区子宫内膜癌主要製造商
    • 亚太地区市场规模与预测（按国家）
    • 亚太地区市场规模和预测（按癌症类型）
    • 按治疗类型分類的亚太市场规模和预测
    • 按诊断方法分類的亚太市场规模和预测
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲子宫内膜癌主要製造商
    • 拉丁美洲市场规模与预测（按国家）
    • 拉丁美洲市场规模与预测（按癌症类型）
    • 拉丁美洲市场规模与预测（按治疗类型）
    • 拉丁美洲市场规模和预测（按诊断方法）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲子宫内膜癌主要製造商
    • 中东和非洲市场规模及预测（按国家）
    • 中东和非洲市场规模及预测（按癌症类型）
    • 中东和非洲市场规模和预测（按治疗类型）
    • 中东和非洲市场规模及预测（按诊断方法）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 的其余部分

第 11 章：主要供应商分析 - 子宫内膜癌产业

  • 竞争仪表板
  • 公司简介
    • Pfizer Inc.
    • Bristol Myers Squibb Company
    • Merck & Co. Inc.
    • Novartis International AG
    • AstraZeneca PLC
    • Genentech Inc. (Roche)
    • GlaxoSmithKline PLC
    • Johnson & Johnson
    • Eli Lilly and Company
    • AbbVie Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Bayer AG
    • Sanofi SA
    • Hoffmann-La Roche Ltd.
    • Exelixis Inc.
    • Others

第 12 章：360 度分析师视角

第 13 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV4183

REPORT HIGHLIGHT

Endometrial Cancer Market size was valued at USD 26,394.53 million in 2023, expanding at a CAGR of 5.80% from 2024 to 2032.

Endometrial cancer is a form of cancer that originates from the cellular growth within the uterus, which is the hollow, pear-shaped organ in the pelvis responsible for fetal development. In the United States, it is the most prevalent cancer impacting the reproductive system of women and individuals assigned female at birth (AFAB). This type of cancer predominantly occurs following menopause. Approximately 3% of women and individuals with AFAB will be diagnosed with uterine cancer at some stage in their lives, with around 65,000 new cases reported annually.

Endometrial Cancer Market- Market Dynamics

The increasing prevalence of endometrial cancer is anticipated to propel market expansion.

As the number of endometrial cancer cases escalates, there is an increasing demand for efficient diagnostic tools and services. This encompasses the utilization of imaging technologies, such as ultrasound and MRI, along with biopsy procedures. Improved awareness and screening practices can facilitate earlier diagnoses, which are crucial for enhancing treatment outcomes. According to the World Cancer Research Fund International, there were 420,368 new cases of endometrial cancer reported in 2022. The ongoing research and development, along with advancements in treatment modalities, may present growth opportunities for the market. However, limited access to healthcare services could hinder market growth.

Endometrial Cancer Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 5.80% over the forecast period (2024-2032)

Based on Type of Cancer segmentation, Endometrial Carcinoma was predicted to show maximum market share in the year 2023

Based on Type of Therapy segmentation, Chemotherapy was the leading type in 2023

Based on Diagnosis Method segmentation, Biopsy was the leading type in 2023

Based on region, North America was the leading revenue generator in 2023

Endometrial Cancer Market- Segmentation Analysis:

The Global Endometrial Cancer Market is segmented on the basis of Type of Cancer, Type of Therapy, Diagnosis Method, and Region.

The market is divided into two categories based on the Type of Cancer: Endometrial Carcinoma, Uterine Sarcomas, and Others. Endometrial Carcinoma dominates the market. Endometrial carcinoma is a type of cancer that originates in the lining of the uterus (endometrium). It accounts for the majority of uterine cancers and is usually diagnosed in postmenopausal women.

The market is classified into three segments according to the Type of Therapy: Immunotherapy, Radiation Therapy, Chemotherapy, and Others. The Chemotherapy segment holds a dominant position within the market. It is widely recognized as one of the primary treatment options for advanced, recurrent, or aggressive types of endometrial cancer.

The market is segmented into four categories according to the Diagnosis Method: Biopsy, Pelvic Ultrasound, Hysteroscopy, CT scan, and others. Biopsy holds a predominant position in the market. The significance of biopsies in the early detection and diagnosis of endometrial cancer is paramount, as they directly affect treatment choices and the demand for diagnostic tools and methodologies.

Endometrial Cancer Market- Geographical Insights

North America leads the market, primarily due to advancements in diagnostic methodologies. The region is characterized by a strong healthcare system that includes numerous established cancer treatment centers and specialized facilities, all equipped with cutting-edge diagnostic technologies. This infrastructure facilitates a holistic approach to cancer care, encompassing both diagnosis and treatment. Annually, around 400,000 patients are diagnosed with cancer at NCI-Designated Cancer Centers. Europe ranks as the second largest region for market growth, attributed to heightened awareness and the implementation of screening programs. The global market is anticipated to grow further as awareness, diagnostic capabilities, and treatment alternatives continue to enhance across various regions.

Endometrial Cancer Market- Competitive Landscape:

The Endometrial Cancer Market exhibits a high level of competition, propelled by innovations in diagnostics, treatment modalities, and emerging technologies focused on enhancing patient outcomes. Numerous firms are competing for market share in sectors such as biopsy instruments, chemotherapeutic drugs, targeted therapies, and immunotherapies. Significant investments in research and development are being made to create novel treatment options, including immunotherapies, targeted therapies, and combination approaches. Advancements such as liquid biopsy and genetic testing are increasingly recognized for their potential in early detection and personalized treatment strategies. Companies that can efficiently navigate the regulatory approval process are positioned to gain a competitive edge, particularly in rapidly evolving areas like immunotherapy.

Recent Developments:

On February 5, 2024, Novartis announced that it has reached an agreement to initiate a voluntary public takeover bid for MorphoSys AG, a biopharmaceutical company based in Germany that specializes in the development of innovative oncology treatments.

A recent trial of an innovative antibody drug, which administers powerful chemotherapy directly to cancer cells, is progressing to a phase III study for patients suffering from advanced or recurrent endometrial cancer.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ENDOMETRIAL CANCER MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Pfizer Inc.
  • Bristol Myers Squibb Company
  • Merck & Co. Inc.
  • Novartis International AG
  • AstraZeneca PLC
  • Genentech Inc. (Roche)
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Eli Lilly and Company
  • AbbVie Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Bayer AG
  • Sanofi S.A.
  • Hoffmann-La Roche Ltd.
  • Exelixis Inc.
  • Others

GLOBAL ENDOMETRIAL CANCER MARKET, BY TYPE OF CANCER- MARKET ANALYSIS, 2019 - 2032

  • Endometrial Carcinoma
  • Uterine Sarcomas
  • Others

GLOBAL ENDOMETRIAL CANCER MARKET, BY TYPE OF THERAPY- MARKET ANALYSIS, 2019 - 2032

  • Immunotherapy
  • Radiation Therapy
  • Chemotherapy
  • Others

GLOBAL ENDOMETRIAL CANCER MARKET, BY DIAGNOSIS METHOD- MARKET ANALYSIS, 2019 - 2032

  • Biopsy
  • Pelvic Ultrasound
  • Hysteroscopy
  • CT scan
  • Others

GLOBAL ENDOMETRIAL CANCER MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Endometrial Cancer Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Endometrial Cancer Market Snippet by Type of Cancer
    • 2.1.2. Endometrial Cancer Market Snippet by Type of Therapy
    • 2.1.3. Endometrial Cancer Market Snippet by Diagnosis Method
    • 2.1.4. Endometrial Cancer Market Snippet by Country
    • 2.1.5. Endometrial Cancer Market Snippet by Region
  • 2.2. Competitive Insights

3. Endometrial Cancer Key Market Trends

  • 3.1. Endometrial Cancer Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Endometrial Cancer Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Endometrial Cancer Market Opportunities
  • 3.4. Endometrial Cancer Market Future Trends

4. Endometrial Cancer Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Endometrial Cancer Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Endometrial Cancer Market Landscape

  • 6.1. Endometrial Cancer Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Endometrial Cancer Market - By Type of Cancer

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type of Cancer, 2023 & 2032 (%)
    • 7.1.2. Endometrial Carcinoma
    • 7.1.3. Uterine Sarcomas
    • 7.1.4. Others

8. Endometrial Cancer Market - By Type of Therapy

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Type of Therapy, 2023 & 2032 (%)
    • 8.1.2. Immunotherapy
    • 8.1.3. Radiation Therapy
    • 8.1.4. Chemotherapy
    • 8.1.5. Others

9. Endometrial Cancer Market - By Diagnosis Method

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Diagnosis Method, 2023 & 2032 (%)
    • 9.1.2. Biopsy
    • 9.1.3. Pelvic Ultrasound
    • 9.1.4. Hysteroscopy
    • 9.1.5. CT scan
    • 9.1.6. Others

10. Endometrial Cancer Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Endometrial Cancer Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Endometrial Cancer Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Endometrial Cancer Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Endometrial Cancer Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Endometrial Cancer Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Endometrial Cancer Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Pfizer Inc.
    • 11.2.2. Bristol Myers Squibb Company
    • 11.2.3. Merck & Co. Inc.
    • 11.2.4. Novartis International AG
    • 11.2.5. AstraZeneca PLC
    • 11.2.6. Genentech Inc. (Roche)
    • 11.2.7. GlaxoSmithKline PLC
    • 11.2.8. Johnson & Johnson
    • 11.2.9. Eli Lilly and Company
    • 11.2.10. AbbVie Inc.
    • 11.2.11. Teva Pharmaceutical Industries Ltd.
    • 11.2.12. Bayer AG
    • 11.2.13. Sanofi S.A.
    • 11.2.14. Hoffmann-La Roche Ltd.
    • 11.2.15. Exelixis Inc.
    • 11.2.16. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us